Lexicon Pharmaceuticals (LXRX) Change in Acquisitions & Divestments (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 17 years of Change in Acquisitions & Divestments data on file, last reported at $35.7 million in Q1 2026.

• Change in Acquisitions & Divestments for Q1 2026 came in at $35.7 million, down 66.18% year-over-year; the trailing twelve-month figure through Mar 2026 was $183.0 million (down 47.25% YoY), and the FY2025 annual result was $252.9 million, down 19.57% from the prior year.
• Change in Acquisitions & Divestments advanced to $35.7 million in Q1 2026 per LXRX's latest filing, from $27.0 million in the prior quarter.
• Over five years, Change in Acquisitions & Divestments peaked at $105.6 million in Q1 2025 and troughed at $8.7 million in Q2 2022.
• A 5-year average of $49.5 million and a median of $41.5 million in 2025 frame the typical range for Change in Acquisitions & Divestments.
• The sharpest annual moves came in 2023 and 2025: Change in Acquisitions & Divestments surged 447.43% in 2023, then plunged 66.25% in 2025.
• A 5-year view of Change in Acquisitions & Divestments shows it stood at $26.0 million in 2022, then soared by 99.95% to $52.0 million in 2023, then surged by 53.85% to $80.0 million in 2024, then sank by 66.25% to $27.0 million in 2025, then jumped by 32.21% to $35.7 million in 2026.
• Business Quant data shows LXRX's Change in Acquisitions & Divestments at $35.7 million in Q1 2026, $27.0 million in Q4 2025, and $78.8 million in Q3 2025.